GlobalData on MSN22h
Takeda broadens its deal with BridGene for up to $770mBridgene and Takeda have inked a deal worth $770m to develop small molecules for immunology and neurology. Takeda will pay ...
BridGene strikes another partnership with Takeda as the latter company continues its dealmaking streak, following high-ticket ...
GlobalData on MSN1d
EMA approves Takeda’s Takhzyro pre-filled pen option for HAEThe current approval of Takeda’s Takhzyro pre-filled pen is an addition to the existing 150 mg and 300 mg pre-filled syringes ...
Takeda has returned to BridGene Biosciences for another small-molecule collaboration—this time focused on immunology as well ...
Takeda, a global biopharmaceutical company with a manufacturing site in Stanton Springs, unveiled its new Biomedical Waste ...
BridGene Biosciences Inc. has entered a strategic collaboration and licensing agreement with Takeda through which it will use ...
Takeda (TAK) announced that the EMA has approved an additional two mL pre-filled pen option for Takhzyro for subcutaneous administration in ...
Privately-held BridGene Biosciences has announced a strategic collaboration and licensing agreement with Japan’s Takeda. The ...
TOKYO (Reuters) -Takeda Pharmaceutical said on Thursday its CEO Christophe Weber will retire after more than a decade at the helm of Japan's biggest drugmaker as the company upped its full-year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback